Korro Bio, Inc.

Korro Bio is a biotechnology company dedicated to developing and commercializing a new class of RNA therapies that harness the body's natural RNA editing machinery. Their innovative platform, Oligonucleotide Promoted Editing of RNA (OPERA), utilizes the ADAR enzyme to make precise, single-base RNA edits, offering a novel approach to treating debilitating and life-threatening diseases. This method provides a more precise and flexible alternative to existing gene editing and gene therapy approaches, with the potential to address a wide range of diseases.

Based in Cambridge, Massachusetts, Korro Bio is a rapidly growing company with a strong team of researchers and industry veterans. Their focus areas include the liver and central nervous system (CNS), targeting disease-causing sequences that are responsive to the safe and targeted editing of RNA. The company has raised significant funding to advance its research and development pipeline, positioning itself as a leader in the field of RNA editing therapeutics.

Korro Bio is a biotechnology company dedicated to developing a new class of RNA therapies that are informed by human genetics and disease biology. Their mission is to discover, develop, and commercialize these therapies in order to improve the lives of patients suffering from debilitating and life-threatening diseases.

Korro Bio cultivates a culture of innovation and collaboration, characterized by a commitment to scientific excellence and a drive to deliver life-changing treatments for patients with debilitating diseases. The company values individuals who think differently, embrace simplicity in complex methodologies, and share a passion for developing transformative genetic medicines.

Korro Bio is committed to building a diverse and inclusive workplace where all employees feel valued and respected. They actively seek out individuals from a variety of backgrounds and experiences and are building a team with diverse perspectives to create a more innovative and equitable environment.